Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

A large body of preclinical and clinical data shows that the central melanocortin system is a promising therapeutic target for treating various metabolic disorders such as obesity and cachexia, as well as anorexia nervosa. Setmelanotide, which functions by engaging the central melanocortin circuitry, was approved by the FDA in 2020 for use in certain forms of syndromic obesity. Furthermore, the FDA approvals in 2019 of two peptide drugs targeting melanocortin receptors for the treatment of generalized hypoactive sexual desire disorder (bremelanotide) and erythropoietic protoporphyria-associated phototoxicity (afamelanotide) demonstrate the safety of this class of peptides. These approvals have also renewed excitement in the development of therapeutics targeting the melanocortin system. Here, we review the anatomy and function of the melanocortin system, discuss progress and challenges in developing melanocortin receptor-based therapeutics, and outline potential metabolic and behavioural disorders that could be addressed using pharmacological agents targeting these receptors. © 2023. Springer Nature Limited.


Patrick Sweeney, Luis E Gimenez, Ciria C Hernandez, Roger D Cone. Targeting the central melanocortin system for the treatment of metabolic disorders. Nature reviews. Endocrinology. 2023 Sep;19(9):507-519

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 37365323

View Full Text